Our findings demonstrate the inhibitory effect of circ-CDK14 silencing on OS progression by targeting the miR-198/E2F2 axis, establishing a strong rationale for decreasing circ-CDK14 as a novel therapeutic strategy for OS.
Silencing of circ-CDK14 suppresses osteosarcoma progression through the miR-198/E2F2 axis.